In current clinical applications, macropinocytosis, a non-selective endocytic pathway, is being widely explored for the delivery of anti-cancer drugs, especially in KRAS-mutated cancers (e.g., lung cancer), and shows significant potential. This evidence concerns the gene KRAS and cancer.